Cat. No.: HY-19332

Kifunensine

(Synonyms: FR-900494)

16 Cited Publications

Avis client

Based on 16 publication(s) in Google Scholar

Kifunensine, a potent and selective inhibitor of class I α-mannosidases isolated from Actinomycete, prevents α-mannosidases I from trimming mannose residues on glycoproteins. Kifunensine inhibits ERAD.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.90%
CAS No.: 109944-15-2
Formule: C₈H₁₂N₂O₆
Masse moléculaire:232.19

Stockage:

Powder -20°C, 3 years ; In solvent -80°C, 2 years , -20°C, 1 year

Kifunensine Chemical Structure

CAS No.: 109944-15-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (16)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

In Vitro

Kifunensine, an alkaloid from actinomycete Kitasatosporia kifunense 9482, is the most efficient nhibitor of a-mannosidase I, blocking N-glycan synthesis at an8GlcNAc₂ (Man8) or Man9GlcNAc₂ (Man9) stage^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[3].

Cell Line:

Hybridoma cells expressing a human IgG1 monoclonal Antibody^[3].
Concentration:

2 μg/mL.
Incubation Time:

4 days.
Result:

Significantly reduced the lentil lectin binding.
Kifunensine is the most effective among the inhibitors tested in producing antibodies containing oligomannose residues without fucose.

In Vivo

Animal Model:

BALB/c mice^[3].
Dosage:

5 mg/kg.
Administration:

IV via tail vein.
Result:

There was no significant difference in the serum levels of anti-TEM B mAb generated from cells treated with or without kifunensine in the 7-day period.

Chemical Information

CAS No. 109944-15-2
Appearance Solid
Masse moléculaire 232.19
Formule C₈H₁₂N₂O₆
Color White to off-white
SMILES

O=C(N1[C@@](N2)([H])[C@@H](O)[C@@H](O)[C@H](O)[C@H]1CO)C2=O
Synonyms

FR-900494
Structure Classification
- Alkaloids
- Piperidine Alkaloids
Initial Source
- Microorganisms
actinomycete
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (16)

All WBHistological Imaging/Staining

Sort by:

Journal Impact Factor

Nat Commun

Chimeras co-targeting antigens and FcγRIIb trigger degradation of extracellular soluble proteins and pathological aggregates. [Abstract]

2025 Dec 10. PMID: 41372196
Adv Sci (Weinh)

Mannose Promotes β-Amyloid Pathology by Regulating BACE1 Glycosylation in Alzheimer's Disease. [Abstract]

2025 Mar;12(9):e2409105. PMID: 39807036

Kifunensine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(9):e2409105. [Abstract]

Western blot analysis of BACE1 and Nicastrin expression was performed on CHO-APP cells treated with or without mannose (25 mM), with or without Kifunensine (10 μM).

Kifunensine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(9):e2409105. [Abstract]

Immunofluorescence staining of Aβ in cerebrum from 6‐month‐old 5×FAD mice and 5×FAD+Kif (5 mg/kg, daily, iv, 7 days) mice.

Kifunensine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(9):e2409105. [Abstract]

Western blot analysis of BACE1 and Nicastrin expression in cortex and hippocampus of 6‐month‐old 5×FAD mice and 5×FAD+Kif (5 mg/kg, daily, iv, 7 days) mice.
Nat Struct Mol Biol

Structural analyses define the molecular basis of clusterin chaperone function. [Abstract]

2025 Aug 8. PMID: 40781479
Int J Biol Macromol

Manganese inhibits HBV transcription and promotes HBsAg degradation at non-toxic levels. [Abstract]

2024 Nov;280(Pt 2):135764. PMID: 39299429
Protein Sci

Synthetic antibodies targeting EphA2 induce diverse signaling-competent clusters with differential activation. [Abstract]

2025 Jun;34(6):e70145. PMID: 40411427
Protein Sci

Antigen-binding fragments with improved crystal lattice packing and enhanced conformational flexibility at the elbow region as crystallization chaperones. [Abstract]

2024 Jul;33(7):e5081. PMID: 38924648
J Biol Chem

Golgi α-Mannosidases Regulate Cell Surface N-Glycan Type and Ectodomain Shedding of the Transmembrane Protease Corin. [Abstract]

2023 Oct;299(10):105211. PMID: 37660903

Kifunensine purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2023 Oct;299(10):105211. [Abstract]

Western blot analysis of corin proteins in cell lysates from corin-expressing HEK293 cells treated with N-glycosylation inhibitors, including N-linked glycosylation inhibitor-1 (NGI-1), 1-deoxynojirimycin (1-DNJ), kifunensine (KIF, 10 μM, 48 h), and swainsonine (SWA). The activation-cleaved corin protease domain (corin-p) band is shown. Levels of β-tubulin in cell lysates were used to assess protein amounts in each sample.

Kifunensine purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2023 Oct;299(10):105211. [Abstract]

In cell lysates, the ratio of corin-p versus zymogen bands in 1-DNJ-, KIF- (10 μM, 48 h), and SWA-treated samples decreased to 35 ± 3, 35 ± 6, and 62 ± 17% of the vehicle, respectively (n = 3; p = 0.003, 1-DNJ versus the vehicle; p = 0.003, KIF versus the vehicle; p = 0.049, SWA versus the vehicle).
J Cell Physiol

A proton channel, Otopetrin 1 (OTOP1) is N-glycosylated at two asparagine residues in third extracellular loop. [Abstract]

2024 Sep;239(9):e31403. PMID: 39129225
Development

The functional specificity of ERECTA-family receptors in Arabidopsis stomatal development is ensured by molecular chaperones in the endoplasmic reticulum. [Abstract]

2022 Sep 1;149(17):dev200892. PMID: 36052695
Glycobiology

Siglec-15 binds mucin-domain glycoproteins with extended glycans and marks an osteoclast-like, matrix remodeling myeloid state in human tumors. [Abstract]

2026 May 22;36(7):cwag035. PMID: 42286920
bioRxiv

2026 Jun 18.
University of Pennsylvania

2026.
bioRxiv

2025 Aug 08.
SSRN

2025 Apr 24.
bioRxiv

2024 October 31.
bioRxiv

2023 Jul 6.

Solvant et solubilité

In Vitro:

DMSO : 10 mg/mL (43.07 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.3068 mL

21.5341 mL

43.0682 mL

5 mM

0.8614 mL

4.3068 mL

8.6136 mL

10 mM

0.4307 mL

2.1534 mL

4.3068 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.19 mg/mL (5.13 mM); Clear solution

This protocol yields a clear solution of ≥ 1.19 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (11.9 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.19 mg/mL (5.13 mM); Clear solution

This protocol yields a clear solution of ≥ 1.19 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (11.9 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.19 mg/mL (5.13 mM); Clear solution

This protocol yields a clear solution of ≥ 1.19 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (11.9 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Yongao Xiong, et al. Glycoform Modification of Secreted Recombinant Glycoproteins through Kifunensine Addition during Transient Vacuum Agroinfiltration. Int J Mol Sci. 2018 Mar; 19(3): 890.

[2]. Hiroshi Kayakiri, et al. Structure of Kifunensine, a New Immunomodulator Isolated from an Actinomycete. J. Org. Chem. 1989,54,4015-4016.

[3]. Qun Zhou, et al. Development of a Simple and Rapid Method for Producing Non-Fucosylated Oligomannose Containing Antibodies With Increased Effector Function. Biotechnol Bioeng. 2008 Feb 15;99(3):652-65. [Content Brief]

[4]. Hyung Lim Elfrink, et al. Inhibition of Endoplasmic Reticulum Associated Degradation Reduces Endoplasmic Reticulum Stress and Alters Lysosomal Morphology and Distribution. Mol Cells. 2013 Apr 30; 35(4): 291–297. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.3068 mL	21.5341 mL	43.0682 mL	107.6704 mL
	5 mM	0.8614 mL	4.3068 mL	8.6136 mL	21.5341 mL
	10 mM	0.4307 mL	2.1534 mL	4.3068 mL	10.7670 mL
	15 mM	0.2871 mL	1.4356 mL	2.8712 mL	7.1780 mL
	20 mM	0.2153 mL	1.0767 mL	2.1534 mL	5.3835 mL
	25 mM	0.1723 mL	0.8614 mL	1.7227 mL	4.3068 mL
	30 mM	0.1436 mL	0.7178 mL	1.4356 mL	3.5890 mL
	40 mM	0.1077 mL	0.5384 mL	1.0767 mL	2.6918 mL

Keywords

Kifunensine

16 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Kifunensine

Alkaloids Library

Microbial Metabolite Library

Targeted Diversity Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Kifunensine

Activité biologique

Chemical Information

Publications (16)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Kifunensine

Alkaloids Library

Microbial Metabolite Library

Targeted Diversity Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Kifunensine

Activité biologique

Chemical Information

Publications (16)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Kifunensine Related Classifications

HY-19332 Related Classifications